Skip to content

Main Navigation

Vor Bio
  • News & Media
  • Publications
  • Medical Professionals
  • Contact
  • Blog
  • Search
  • About Us
    • Overview
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • Overview
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Overview
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Overview
    • What is AML?
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Join Us
    • Overview
    • Values & Culture
    • Benefits
    • Open Positions
    • Co-Op Program
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts

Publication Programs: Platform

Decentralized manufacturing: from stem cell transplants to the next generation of cellular immunotherapies. Li M, Kassim S.

Cell & Gene Therapy – 2020 June […]

Read More… from Decentralized manufacturing: from stem cell transplants to the next generation of cellular immunotherapies. Li M, Kassim S.

Gene-edited stem cells enable CD-33 directed immune therapy for myeloid malignancies. Borot F, Wang H, Ma Y, Jafarov T, Raza A, Ali AM, and Mukherjee S.

PNAS – 2019 Mar […]

Read More… from Gene-edited stem cells enable CD-33 directed immune therapy for myeloid malignancies. Borot F, Wang H, Ma Y, Jafarov T, Raza A, Ali AM, and Mukherjee S.

Engineering resistance to CD-33 targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo PR, Kiem HP, Walter RB.

Leukemia – 2019 Mar; 33(3):762-808 […]

Read More… from Engineering resistance to CD-33 targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Humbert O, Laszlo GS, Sichel S, Ironside C, Haworth KG, Bates OM, Beddoe ME, Carrillo PR, Kiem HP, Walter RB.

Posts navigation

  • «
  • 1
  • 2
  • 3
  • 4

Share This Post

Recent Vor Voices

  • A Legacy of Hope and Discovery April 10, 2025
  • Earning vs Deserving December 22, 2024
  • Satisfaction in Excellence November 24, 2024
  • Comfort is the Enemy? November 4, 2024
  • Remembering a Life and Embracing Hope: My Family’s Journey with AML and Our Fight for a Cure September 23, 2024
  • Understanding not just the jigsaw piece, but the entire puzzle September 10, 2024
  • Affinity vs Ability: Finding Work That Fits Your Personality August 23, 2024
  • Finding Joy in Work August 19, 2024
  • Fellowship in Action: Our First In-House Manufacturing Run June 26, 2024
Logo Vor Biopharma White

Follow us on social media:

Twitter LinkedIn Instagram

Boston Business Journal Badge 2023 2024
Read more about
working at Vor Bio

  • About Us
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • What is AML?
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Our Investigational Programs
    • Clinical Trials
  • Investors
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts
  • News & Media
  • Publications
  • Join Us
  • Blog

© 2025 Vor Bio

  • Privacy Policy
  • Terms of Use
Recruiting Guidelines

All employment opportunities at Vor Biopharma are managed by our in-house Human Resources Department. Therefore, agency staff and independent recruiters must contact the Human Resources Department directly in order to present candidates or inquire about openings. Please do not contact other Vor Bipharma employees. Your ability to comply with this request will significantly impact any decision we may make about doing business with you.

Please understand that we do not accept unsolicited resumes from any source other than from the candidates themselves. Any agency or independent recruiter must have a signed copy of our agency agreement before presenting candidates. Submission of unsolicited resumes without our signed agreement will not create any implied obligation on our part.

If you wish to be considered for the presentation of candidates, please contact us through careers@vorbio.com. Attach your contact information, your area of specialty, and any marketing information you wish to provide. Someone from the Human Resources Department will contact you directly if there is a business need for your services.